Heart failure (HF) is a clinical syndrome characterized by a number of symptoms (difficulty breathing, malleolar edema, and fatigue) that may be accompanied by signs (increased jugular venous pressure, pulmonary crackling, and peripheral edema) caused by alterations. functional and / or structural cardiac disorders.1 The classification of HF is mainly based on the left ventricular ejection fraction (FEVE). It is considered HF with reduced FEVE when it is equal to or less than 40% and represents approximately 50% of all cases of HF in our environment. The main cause of this is coronary heart disease, although other factors of risk, such as high blood pressure, diabetes mellitus or metabolic syndrome, also contribute. The identification of the underlying cause must be part of the diagnosis as it conditions the prognosis and treatment.
Dapagliflozin; ISGLT2; Chronic heart failure; Reduced ejection fraction
Programa d'Harmonització Farmacoterapèutica. Dapagliflozina per al tractament de la insuficiència cardíaca crònica amb fracció d’ejecció reduïda. Barcelona: Servei Català de la Salut; 2021.
Use this identifier for quote and/or link this documenthttp://hdl.handle.net/11351/6408
This item appears in following collections
The following license files are associated with this item: